FMP
NASDAQ
18.29 USD
0.09 (0.492%)
Mr. Stephen R. Davis J.D.
Healthcare
Biotechnology
https://www.acadia-pharm.com
NASDAQ
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for...
0001070494
US0042251084
004225108
12830 El Camino Real
858 558 2871
US
597
May 27, 2004
0001070494
NASDAQ
Biotechnology
Healthcare
004225108
US0042251084
US
18.29
0.4
1.87M
3.01B
-
17.56-33.99
15.72
-
-
-
-
-49.43
-
https://www.acadia-pharm.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.